[HTML][HTML] Myc oncogene: a druggable target for treating cancers with natural products
Various diseases, including cancers, age-associated disorders, and acute liver failure, have
been linked to the oncogene, MYC. Animal testing and clinical trials have shown that …
been linked to the oncogene, MYC. Animal testing and clinical trials have shown that …
Aberrant Super-Enhancer Landscape in Enzalutamide-Resistant Prostate Cancer Cells
C Cai, Q Liu, H Shan, C Zhong, G Chen… - Genetic Testing and …, 2024 - liebertpub.com
Background: Castration-resistant prostate cancer (CRPC), which has developed resistance
to next-generation antiandrogens, such as enzalutamide (Enz), is a lethal disease …
to next-generation antiandrogens, such as enzalutamide (Enz), is a lethal disease …
Resistance to Endocrine Therapy in Breast Cancer
The foremost cause of female deaths is due to breast cancer. The most frequent type of
breast cancer is hormone-dependent breast cancer, being either progesterone-or estrogen …
breast cancer is hormone-dependent breast cancer, being either progesterone-or estrogen …
CMTM6 deletion affects chemoresistance and macrophage M2 polarization in colorectal cancer cells.
Y Xu, H Li, G You - Biocell, 2024 - search.ebscohost.com
Background: Colorectal cancer (CRC) constitutes the leading cause of death worldwide.
Chemoresistance and tumor immune evasion are critical contributors to therapeutic failure in …
Chemoresistance and tumor immune evasion are critical contributors to therapeutic failure in …
The anthraquinone derivative KA‐4s reduces energy metabolism and enhances the sensitivity of ovarian cancer cells to cisplatin
Y Zhao, X Li, S Xu, Y Yang, Q Chen, J Li… - Molecular … - Wiley Online Library
Ovarian cancer is the leading cause of death from female gynecological cancers. Cisplatin
(DDP) is a first‐line drug for ovarian cancer treatment. Due to DDP resistance, there is an …
(DDP) is a first‐line drug for ovarian cancer treatment. Due to DDP resistance, there is an …